DBVT - DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer | Benzinga
Montrouge, France, October 16, 2023
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee.
"I am pleased to welcome Virginie to the DBV Executive Committee to lead our global financial organization," said Daniel Tassé, Chief Executive Officer, DBV Technologies. "Virginie is collaborative, results-focused, and brings extensive experience in finance, strategy, and global management across the pharmaceutical industry. I know she will bring great value to our leadership team."
Virginie will be responsible for DBV's financial management and operations, information technology, strategic planning, and investor relations. Virginie brings approximately 30 years of diverse experience in the pharmaceutical industry. She most recently served as the Group Performance Director for Pierre Fabre. Prior to this, Virginie held various senior positions at Sanofi, including Chief of Staff to the Sanofi CEO, Global Transformation Office Head, and Chief Financial Officer for India and South Asia. She is trained in finance as a graduate of Ecole Superieure de Gestion where she obtained a Master of Business Administration. Virginie will be based at DBV's headquarters in Montrouge, France.
"I am thrilled to be joining DBV Technologies at such a critical juncture," said Ms. Boucinha. "The Company is ...